Monday, 31 October 2022

Proactive Investors Interview: BioLargo says it is just scratching the surface of commercial opportunities as revenue surges


BioLargo Inc (OTCQB:BLGO) CEO Dennis Calvert tells Proactive's Stephen Gunnion that the company is just scratching the surface of commercial opportunities for its technology as momentum continues to build.

The cleantech group reported third-quarter revenue of about $1.5 million, a 13% increase from Q2 and a 111% increase on Q3, 2021.

Calvert said BioLargo's POOPH pet odor control product and its PFAS removal project will contribute to growing revenues in Q4 and going into 2024, while other projects will also support growth.

Wednesday, 26 October 2022

BioLargo Sets Another New Quarterly Revenue Record

Westminster, CA – October 26, 2022 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, today announced that it has set a new quarterly revenue record, and provided a snapshot of continued business developments.

BioLargo’s President and CEO Dennis P. Calvert commented, “It is remarkable that we were able to improve on Q2’s record-breaking results, and that because of our Q3 performance we have also locked in a record growth rate for the entire year. We are proud of these accomplishments, but not yet satisfied because we believe that we have still just scratched the surface of the commercial opportunities ahead. We intend to continue this trend of meaningful growth, and we are already off to a good start in Q4.”

The company has several key projects that management believes will stimulate accelerated growth through 2023. These are:

  • The expected launch in major retailers of the POOPH pet odor control product by the company’s consumer packaged goods partners at Ikigai, which is expected to start in Q4.
  • Our first PFAS removal project at a large industrial site (announced in August), currently in the initial phase of a multi-phase process, which we expect to continue advancing as we engineer a comprehensive PFAS mitigation plan.
  • Expanded commercial roll-out of the company’s PFAS treatment technology through its growing network of sales rep organizations.
  • Garratt-Callahan’s launch of the jointly developed minimal liquid discharge wastewater treatment product.               
  • Further work on larger engineering projects, including the waste-to-energy conversion plant project in South America, and the company’s work with Ultra Safe Nuclear.

BioLargo generated approximately $1.5 million in company-wide revenue during the third quarter of 2022, representing a 13% increase compared with the second quarter of 2022, and a 111% increase compared with the third quarter of 2021, led by a significant increase in sales of the POOPH pet odor product. Note, however, that these revenue figures are preliminary, and are subject to change pending review by the company's independent registered public accounting firm. The company will include its full results of operations in its quarterly report for the period ended September 30, 2022, due to be filed with the SEC by November 14, 2022. The company also intends to hold an investor webcast and conference call shortly after the filing of its quarterly report to discuss its financial results, and will provide details for participating in this event as soon as they are available.

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative technologies in the cleantech space, including for PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our approach is to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. We have developed a number of key channel partnerships to support the reach of our products and services and maximize their commercial potential. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 90 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue and plans for future operations, and may be identified by words such as “we believe”. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of global and regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Tuesday, 25 October 2022

BioLargo, Inc. Discusses Its PFAS Treatment Solution and Odor Control Technology with The Stock Day Podcast

Source: https://www.newsfilecorp.com/release/141860 

Phoenix, Arizona--(Newsfile Corp. - October 25, 2022) - The Stock Day Podcast welcomed BioLargo, Inc. (OTCQB: BLGO), a company that invents, develops, and commercializes innovative technologies in the cleantech space, including for PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. CEO of BioLargo, Dennis Calvert, joined Stock Day host Everett Jolly.

Jolly began the interview by asking about BioLargo's PFAS treatment technology. Calvert explained the origins of PFAS contamination and how it threatens water around the world. "These forever chemicals can lead to adverse health effects, birth defects, cancer, and all sorts of incredibly negative illnesses, with litigations happening all over the world," explained Calvert.

Calvert then discussed the challenges with current PFAS treatment solutions, which typically generate significant waste, creating an environmental hazard. In contrast, BioLargo's own treatment solution the Aqueous Electrostatic Concentrator (AEC) generates very little solid waste, making it both eco-friendly and logistically sound for customers.

"What is your roll out plan?", asked Jolly. Calvert explained that the company has several channel partners already on board to represent the AEC, and that several additional sales rep organizations have indicated they would also carry the AEC after discussions at recent trade shows. "We have shored up outsourced manufacturing with PRM [(Product Recovery Management)], which gives us the ability to be able to deliver machines and equipment to scale rapidly to combine with our own."

The conversation then turned to BioLargo's pet odor technology. "We have negotiated an arrangement with our partner where we have a cost plus arrangement," said Calvert. "We also [would] participate in the equity of the brand upon exit, equal to 20%," he continued. "That product is now doing over $100,000 per day in sales, which was a significant revenue contribution to our record performance last quarter," he shared. "They are ramping up, and are expecting to enter Walmart stores in November," said Calvert, adding that the company expects these sales to reflect in the fourth quarter and anticipates more major retailers coming onboard.

To close the interview, Calvert elaborated on BioLargo's significant potential as they continue to find adoption for their growing technology solutions. He also encouraged listeners to keep up-to-date on their current and upcoming projects by following the company's blog at https://biolargo.blogspot.com/.

To hear Dennis Calvert's entire interview, follow the link to the podcast here: https://audioboom.com/posts/8180691-biolargo-inc-discusses-its-pfas-treatment-solution-and-odor-control-technology-with-the-stock-d

Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at https://investorshangout.com/

About BioLargo, Inc.

BioLargo, Inc. (OTCQB: BLGO) invents, develops, and commercializes innovative technologies in the cleantech space, including for PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our approach is to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. We have developed a number of key channel partnerships to support the reach of our products and services and maximize their commercial potential. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 90 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding anticipated revenue and plans for future operations, and may be identified by words such as "we believe". These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company's business, results of operations, financial condition, and stock price; the effect of global and regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

About The "Stock Day" Podcast

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America.

SOURCE:
Stock Day Media
(602) 821-1102

Benzinga Interview: Meet The Company On The Front Lines Of The Fight To Keep The Planet Green

 Source: Benzinga (https://www.benzinga.com/markets/penny-stocks/22/10/29397796/meet-the-company-on-the-front-lines-of-the-fight-to-keep-the-planet-green

Dennis Calvert, CEO of BioLargo Inc (BLGO), was a guest on Benzinga’s All Access on October 21, 2022.

BioLargo invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. The company recently achieved 185% growth in Q2 2022, reaching  $1.3 Million in revenue.

Watch the full interview here:

Monday, 17 October 2022

Tonya Chandler's PFAS Webinar in Wisconsin

BioLargo's Director of Commercialization Tonya Chandler has been doing a circuit of presentations to engineers around the country about the state and evolution of the PFAS treatment market. 

This webinar presentation was delivered to a group of engineers in Wisconsin late last month, and is now available to watch right here on our blog. Watch to learn about changes to state limits, federal limits, and PFAS' evolving status as a hazardous substance under CERCLA/RCRA.

Thursday, 13 October 2022

BioLargo’s WEFTEC 2022 Recap

Source: ntradeshows.com
As WEFTEC week comes to close, we reflect on the success of this important conference this year. The BioLargo team came out in force, showing off our sustainable PFAS treatment technology, our cost-effective, low-energy wastewater disinfection and micropollutant removal technology the AOS, and our industry-leading odor and VOC control products.

Our room at the conference hosted an endless stream of technical experts, sales reps, engineers, and other conference attendees, each of whom checked out the demo units for our water treatment technologies!

Representatives from the EPA, which is hard at work shaping regulations for PFAS contaminated water, came to check out and discuss our innovative low-waste PFAS system. We gave interviews for several water sector media outlets including GWI and Water Online (which will be available soon!). We also received verbal commitments from multiple sales representative groups interested in carrying our treatment systems.

A special shout-out to our partners at Garratt-Callahan, with whom we are co-commercializing a new Minimal Liquid Discharge (MLD) wastewater treatment system. We had some great and promising strategy meetings surrounding our customer roll-out plans for this technology at the conference, and we’re more excited than ever for the prospects of this partnership.

Thank you to the hard-working WEFTEC staff for putting on such an excellent event this year. It truly is the best opportunity to develop all-important relationships and advance strategic goals in the water sector.



Thursday, 6 October 2022

BioLargo Secures Product Recovery Management (PRM) as Channel Partner and Contract Manufacturer for BioLargo’s Water Treatment Technologies

Westminster, CA – October 6, 2022 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, announced that it signed a channel partnership agreement with Product Recovery Management, Inc. to sell and distribute BioLargo’s water treatment systems and act as a contract manufacturer.

Product Recovery Management (PRM) (https://www.prmfiltration.com/), based out of Butner, NC, is a UL-certified equipment integrator specializing in remediation services with over 40 years of history serving customers. PRM designs and manufactures treatment systems that address a wide variety of contamination challenges in the remediation and landfill industries, including PFAS contamination. Their Butner operations include a 250,000 square foot manufacturing facility with large-scale fabrication capabilities.

The channel partner agreement grants PRM a license to sell and distribute BioLargo’s innovative water and wastewater treatment technologies, including but not limited to the Aqueous Electrostatic Concentrator (AEC), BioLargo’s effective, affordable, low-waste solution for removing per- and polyfluoroalkyl substances (PFAS) from water. PRM will also be authorized to sell BioLargo’s Advanced Oxidation System (AOS) technology, the energy-efficient and affordable solution for simultaneous water disinfection and micropollutant treatment.

PRM will also be a contract manufacturer for BioLargo’s water treatment technologies, including the AEC, the AOS, as well as other treatment systems designed by BioLargo (e.g., reverse osmosis systems).

“PRM has substantial expertise and infrastructure to support the roll-out and manufacturing of our cleantech systems. This relationship will allow us to more readily meet the growing demand for our systems and expand our reach into the market. We have already begun scoping our first project together,” says Randall Moore, President of BioLargo Engineering, Science & Technologies (BioLargo’s engineering subsidiary – www.BioLargoEngineering.com).

“BioLargo’s AEC and AOS technologies are unique and valuable tools for targeted removal of tough-to-treat water contaminants including PFAS and micropollutants, both of which currently lack effective and affordable options in the marketplace. We recognized in BioLargo a commitment to serve customers with technical excellence and reliable results. We look forward to working with the BioLargo team,” said Robert Phillips, Jr., President of Product Recovery Management.

 

About PRM:

Headquartered in Butner, NC. PRM was founded in 1990 by Mel and Brian Phillips. Originating as Phillips Electric Company in 1976, PRM is now a premier environmental remediation and landfill gas company with systems operating across the globe. PRM is an Original Equipment Manufacturer (OEM) of pollution control and other equipment, mainly focused on the Remediation and Landfill Industries. Their experiences and talents are well diversified.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative technologies in the cleantech space, including for PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our approach is to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. We have developed a number of key channel partnerships to support the reach of our products and services and maximize their commercial potential. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 90 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue and plans for future operations, and may be identified by words such as “we believe”. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of global and regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.